欢迎来到天天文库
浏览记录
ID:53727482
大小:214.04 KB
页数:3页
时间:2020-04-20
《培美曲塞联合顺铂二线治疗晚期胃癌的临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、临床肿瘤学杂志2014年3月第19卷第3期ChineseClinicalOncolo~,Mar.2014,Vo1.19,No.3·255··临床应用·培美曲塞联合顺铂二线治疗晚期胃癌的临床观察213000江苏常州常州市武进人民医院肿瘤科焦安娜,金建华,陆文斌,邓建忠,张华,刘允刚【摘要】目的评价培美曲塞联合顺铂二线治疗晚期胃癌的疗效及不良反应。方法选取2011年12月至2013年2月46例一线化疗失败的晚期胃癌患者,给予培美曲塞联合顺铂二线治疗,具体为:培美曲塞500mg/m静滴,d.;顺铂25m
2、g/m静滴,d,~d;21天为1周期。根据RECIST1.0版标准评价近期疗效并计算有效率(RR)和疾病控制率(DCR),同时采用NCICTC3.0标准评价毒副反应,随访无进展生存期(PFS)和总生存期(OS)。结果46例均可评价近期疗效,其中无完全缓解病例,部分缓解10例,稳定12例,进展24例,RR为21.7%,DCR为47.8%。随访3—20个月,中位PFS和Os分别为3.5个月和8.4个月。全组化疗后的KPS评分为(77.6±4.3)分,高于化疗前的(65.7±5.0)分(P3、但化疗前后止痛药使用率的差异无统计学意义(P>O.05)。主要毒副反应为1~3级骨髓抑制和胃肠道不良反应,4级毒副反应发生率极低,仅1例4级白细胞减少;2例1级肝功能异常;患者均无肾功能异常、发热、皮疹及化疗相关性死亡。结论培美曲塞联合顺铂二线治疗晚期胃癌的疗效较好,且毒副反应轻,耐受性好。【关键词】晚期胃癌;培美曲塞;顺铂;化学治疗中图分类号:R735.2文献标识码:A文章编号:1009—0460(2014)03—0255—03Clinicalobservationofpemetrexedcom4、binedwithcisplatinassecond-linetreatmentinadvancedgastriccancerJIAOAnna,JINJianhua,LUWenbin,DENGJianzhong,ZHANGHua,LIUYungang.DepartmentofOncolo—gY,ChangzhouWujinPeople'sHospital,Changzhou213000,China【Abstract】ObjectiveToevaluatetheefficacyandtoxicity5、ofpemetrexedcombinedwithcisplatinassecond—linetreatmentinadvancedgastriccancer.MethodsForty—sixpatientswithadvancedgastriccancerwhohadpreviouslyfailedtofirst—linechemotherapyfromDecember2011toFebruary2013receivedpemetrexed(500mg/miv,d1)combinedwithcis6、platin(25mg/miv,d1-d3)assecond—linetreatment.Twenty—onedayswasacycle.Theresponseevaluationcriteriainsolidtumors(RECIST)1.0wasemployedtoevaluatetheshort-termeficacyandcalculatedtheresponserate(RR)anddiseasecontrolrate(DCR).ThetoxicitywasevaluatedusingN7、CICTC3.0criteria.Progression·freesurvival(PFS)andoverallsurvival(OS)werecalculatedfromthedateoffollow-up.ResultsForty-sixpatientswereevaluableforshort—termeficacy.Therewere10casesofpartialresponse,12ofstablediseaseand24ofprogressivediseasewithRRof21.78、%andDCRof47.8%.Thefollow—uprangedfrom3to20months.ThemedianPFSandOSwere3.5and8.4months.re—spectively.TheKPSwas77.6-+4.3afterchemotherapy,higherthan65.7+5.0beforechemotherapy,buttherewasnosignificantdiffer—enceonpainkillerusagebeforeandafterchem
3、但化疗前后止痛药使用率的差异无统计学意义(P>O.05)。主要毒副反应为1~3级骨髓抑制和胃肠道不良反应,4级毒副反应发生率极低,仅1例4级白细胞减少;2例1级肝功能异常;患者均无肾功能异常、发热、皮疹及化疗相关性死亡。结论培美曲塞联合顺铂二线治疗晚期胃癌的疗效较好,且毒副反应轻,耐受性好。【关键词】晚期胃癌;培美曲塞;顺铂;化学治疗中图分类号:R735.2文献标识码:A文章编号:1009—0460(2014)03—0255—03Clinicalobservationofpemetrexedcom
4、binedwithcisplatinassecond-linetreatmentinadvancedgastriccancerJIAOAnna,JINJianhua,LUWenbin,DENGJianzhong,ZHANGHua,LIUYungang.DepartmentofOncolo—gY,ChangzhouWujinPeople'sHospital,Changzhou213000,China【Abstract】ObjectiveToevaluatetheefficacyandtoxicity
5、ofpemetrexedcombinedwithcisplatinassecond—linetreatmentinadvancedgastriccancer.MethodsForty—sixpatientswithadvancedgastriccancerwhohadpreviouslyfailedtofirst—linechemotherapyfromDecember2011toFebruary2013receivedpemetrexed(500mg/miv,d1)combinedwithcis
6、platin(25mg/miv,d1-d3)assecond—linetreatment.Twenty—onedayswasacycle.Theresponseevaluationcriteriainsolidtumors(RECIST)1.0wasemployedtoevaluatetheshort-termeficacyandcalculatedtheresponserate(RR)anddiseasecontrolrate(DCR).ThetoxicitywasevaluatedusingN
7、CICTC3.0criteria.Progression·freesurvival(PFS)andoverallsurvival(OS)werecalculatedfromthedateoffollow-up.ResultsForty-sixpatientswereevaluableforshort—termeficacy.Therewere10casesofpartialresponse,12ofstablediseaseand24ofprogressivediseasewithRRof21.7
8、%andDCRof47.8%.Thefollow—uprangedfrom3to20months.ThemedianPFSandOSwere3.5and8.4months.re—spectively.TheKPSwas77.6-+4.3afterchemotherapy,higherthan65.7+5.0beforechemotherapy,buttherewasnosignificantdiffer—enceonpainkillerusagebeforeandafterchem
此文档下载收益归作者所有